FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Enhertu is projected to reach $13.9bn in sales by 2030, according to GlobalData’s Pharma Intelligence Center.
Enhertu is projected to reach $13.9bn in sales by 2030, according to GlobalData’s Pharma Intelligence Center.
What's Your Reaction?
